Merck Sees Pivotal Victory for $3B Eye Disease Prospect
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion takeover.
A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies.
Merck
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies”
biopharma dive — Merck reveals study success, and possible safety worries, for eye drug hopeful“Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion takeover.”
fierce biotech — <a href="/biotech/merck-co-uncorks-pivotal-victory-3b-eye-disease-prospect" hreflang="en">Merck sees pivotal victory for $3B eye disease prospect</a>